Roivant Sciences News - September 2026
🔴 Roivant Sciences is trading 24% down today in after-hours trading with no specific negative announcement identified
Roivant Sciences is trading 23.81% lower at $29.12 after-hours on September 22, 2026, versus the regular-session close of $38.22; available coverage identifies...
🔴 Roivant Sciences is trading 24.49% down in after-hours trading amid possible after-hours liquidity or data anomaly
Roivant Sciences is trading at $30.03, down 24.49% after closing at $39.77 on September 18, 2026; the move may reflect an after-hours liquidity or data anomaly...
🔴 Roivant Sciences is trading 15.41% down in after-hours trading; no reliable catalyst identified
Roivant Sciences is trading 15.41% down at $34.53, with the after-hours reversal remaining unexplained. - Closed at $40.82 on September 11, 2026. - No...
Roivant Reports Positive Phase 2 Trial Data for Mosliciguat, Initiates Phase 3 Study
Roivant Sciences announced positive results from its Phase 2 PHocus clinical trial for mosliciguat in patients with pulmonary hypertension associated with...
🟢 Roivant Sciences is trading 13.46% up today after positive Phase 2 PHocus results
Roivant Sciences is trading 13.46% up now at $39.63 after positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with...
Roivant Surges 21% on Blockbuster Lung Drug Data — But Can a Phase 2 Win Sustain a $7 Billion Bet?
Shares of Roivant Sciences vaulted +21.2% to $42.33 this morning after the company disclosed what it called the strongest efficacy ever recorded in a...
🟢 Roivant Sciences surges 21% in pre-market on positive mosliciguat PHocus topline results
Roivant Sciences is trading at $42.33, up +21.19%, following the announcement of positive Phase 2 PHocus topline results for mosliciguat. The positive results...